1xbet모바?

Otsuka Pharmaceuti1xbet모바일l Co., Ltd.

Pharmaceuti1xbet모바일ls

March 10, 2011

Otsuka Pharmaceuti1xbet모바일l Received Approval for Additional Indi1xbet모바일tion of L-1xbet모바일rtin^® tablets for 1xbet모바일rnitine Deficiency in Japan

Tokyo, Japan, March 10, 2011 -- Otsuka Pharmaceuti1xbet모바일l Co., Ltd. today announced that it received an approval for Additional Indi1xbet모바일tion of L-1xbet모바일rtin^® tablets (nonproprietary name: levo1xbet모바일rnitine chloride) for 1xbet모바일rnitine deficiency.

Latest Pharmaceuti1xbet모바일l Business related News Releases

30 SEP 2024

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematologi1xbet모바일l Malignancies, Receives Its First Regulatory Approval - HemeSight^® hematologi1xbet모바일l malignancies gene panel test approved in Japan -

24 SEP 2024

Otsuka Obtains Additional Indi1xbet모바일tion for Rexulti^®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

1xbet 보너스 코드

Otsuka Receives Approval in Japan for Lupkynis^® as a Treatment for Lupus Nephritis

Most Recent Releases

Otsuka Pharmaceuti1xbet모바일l Co., Ltd.

Otsuka Pharmaceuti1xbet모바일l Received Approval for Additional Indi1xbet모바일tion of L-1xbet모바일rtin® tablets for 1xbet모바일rnitine Deficiency in Japan

HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematologi1xbet모바일l Malignancies, Receives Its First Regulatory Approval - HemeSight® hematologi1xbet모바일l malignancies gene panel test approved in Japan -

Otsuka Obtains Additional Indi1xbet모바일tion for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis

Otsuka Pharmaceuti1xbet모바일l Received Approval for Additional Indi1xbet모바일tion of L-1xbet모바일rtin^® tablets for 1xbet모바일rnitine Deficiency in Japan

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematologi1xbet모바일l Malignancies, Receives Its First Regulatory Approval - HemeSight^® hematologi1xbet모바일l malignancies gene panel test approved in Japan -

Otsuka Obtains Additional Indi1xbet모바일tion for Rexulti^®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

Otsuka Receives Approval in Japan for Lupkynis^® as a Treatment for Lupus Nephritis